Clinical Trials
51 trialsHyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
University of Rochester
ALERTCML
University of Alabama at Birmingham
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
APEX
Cogent Biosciences, Inc.
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
ACCESS
Center for International Blood and Marrow Transplant Research
OPTIC
Takeda
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute
IAMFIT
Children's Hospital of Philadelphia
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Ascentage Pharma Group Inc.
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
Peking University People's Hospital
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
University of Pittsburgh
A Study of ONO-7475 in Patients With Acute Leukemias
Ono Pharmaceutical Co., Ltd.
FluBuATG
Dartmouth-Hitchcock Medical Center
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Takeda
OPTIC-2L
Takeda
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Kiadis Pharma
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
ENESTnd
Novartis
UF-BMT-MRD-101
University of Florida
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
National Institutes of Health Clinical Center (CC)
Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation
University of Wisconsin, Madison
Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery
University of Wisconsin, Madison
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
Stanford University
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
Il-Yang Pharm. Co., Ltd.
Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease
University of Kansas Medical Center
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
National Institutes of Health Clinical Center (CC)
Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
University of Massachusetts, Worcester
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
Il-Yang Pharm. Co., Ltd.
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
Hoffmann-La Roche
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia
Exelixis
Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine
Assistance Publique Hopitaux De Marseille
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
Merck Sharp & Dohme LLC
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
Merck Sharp & Dohme LLC
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
Teva Branded Pharmaceutical Products R&D, Inc.
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Jiangsu HengRui Medicine Co., Ltd.
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
Dana-Farber Cancer Institute
ENEST
Novartis
Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)
Technische Universität Dresden
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
Radboud University Medical Center